FY25 Results Investor Briefing
Released
Released
Announcement PDF
ASX Announcement
22 August 2025
FY25 Results Investor Briefing
Cogstate Ltd (ASX:CGS) has today released an Investor Briefing that provides a summary of the financial
results for the year ended 30 June 2025 and also provides commentary in respect of the business and financial
outlook.
The presentation material is attached to this announcement.
Investors are invited to join a live webcast and Q&A hosted by Brad O’Connor, CEO, Darren Watson, CFO and
Rachel Colite Executive Vice President, Clinical Trials on Friday 22 August 2025 at 9:00am Australian Eastern
Standard Time.
Please register at: https://investors.cogstate.com/webinars/7PldLP-cogstate-full-year-fy25-results
Additionally, a video recording of the presentation will be available within 24 hours following the presentation at
the Cogstate Investor Centre homepage: https://investors.cogstate.com.
This announcement was authorised for release by Cogstate CEO, Brad O’Connor.
Important Upcoming Dates
To stay up to date, sign up to the Cogstate Investor Hub: https://investors.cogstate.com
1. Thursday 16 October 2025 at 11am AEST
Annual General Meeting of Shareholders
Location: Melbourne Australia and online
2. Friday 7th November 2025 from 9am-2pm AEDT
Shareholder Day (in-person):
Location: Melbourne Australia.
Register here
For further information contact: investor@cogstate.com
FY24 Investor Briefing | Page 1
About Cogstate
Cogstate Ltd (ASX: CGS) is a neuroscience technology company optimising brain health assessments to advance
the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide
rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support partners
in the delivery of electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper
assessments with real-time data capture. The company’s clinical trials solutions include quality assurance services
for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting.
For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical
companies and academic institutions, and the clinical care needs of physicians and patients around the world. In the
Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and
scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform
patients and save physician time. For more information, please visit www.cogstate.com.
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of
Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied
upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in
this announcement, nor any information made available to you is, or shall be relied upon as, a promise, representation,
warranty or guarantee, whether as to the past, present or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”,
“intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are
intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position
and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided
in this announcement are based on assumptions and contingencies that are subject to change without notice and
involve known and unknown risks and uncertainties and other factors that are beyond the control of Cogstate, its
directors and management. Forward-looking statements are provided as a general guide only and should not be
relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such
statements and any projections and assumptions on which these statements are based. These statements may
assume the success of Cogstate's business strategies, including the that the results of any of those strategies will be
realised in the period for which the forward-looking statement may have been prepared or otherwise. For example,
Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in that period,
or a subsequent period, and the rate of enrolment in trials of its customers, which are influenced by factors that are
outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or
regulations, none of Cogstate, its representatives or advisers, assumes any obligation to update these forwardlooking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of
achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters
contained in this announcement. The forward-looking statements are based on information available to Cogstate as
at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of
Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated information,
whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.
Indications of, and guidance or outlook on, future earnings or financial position or performance are also forwardlooking statements.
FY24 Investor Briefing | Page 2
Full Year
FY2025 Results
22nd August 2025
© 2025 Cogstate Ltd. All rights reserved.
Disclaimer
This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general nature
and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in
accordance with the requirements of the Corporations Act. This presentation may contain statements, opinions, projections,
forecasts and other material (forward looking statements), based on various assumptions. Those assumptions may or may not prove
to be correct. None of Cogstate, its respective officers, employees, agents, advisers or any other person named in this presentation
makes any representation as to the accuracy or likelihood of fulfilment of any forward-looking statements or any of the assumptions
upon which they are based.
The information contained in this presentation does not take into account the investment objectives, financial situation or particular
needs of any recipient and is not financial product advice. Before making an investment decision, recipients of this presentation
should consider their own needs and situation and, if necessary, seek independent, professional advice.
To the extent permitted by law, Cogstate and its respective officers, employees, agents and advisers give no warranty,
representation or guarantee as to the accuracy, completeness or reliability of the information contained in this presentation. Further,
none of Cogstate and its respective officers, employees, agents and advisers accept, to the extent permitted by law, responsibility
for any loss, claim, damages, costs or expenses arising out of, or in connection with, the information contained in this presentation.
Any recipient of this presentation should independently satisfy themselves as to the accuracy of all information contained herein.
2
Growing Scale, Elevated Market Presence
Proven Leadership in Digital Assessment:
Essential CNS Research Partner:
Two decades of validated expertise in sensitive,
standardised digital cognitive tests, working with top
pharma and biotech companies and supported by
peer-reviewed research.
Optimised data collection for all clinical measures in
complex CNS trials from early research through
regulatory submission, streamlining operations and
delivering actionable insights.
Tech-Driven, Industry-Leading Platform:
Trusted Precision in CNS Trials:
Integrated solutions, global rater training and
monitoring, predictive analytics and emerging AIenablement drive data quality, compliance, and
faster decision-making.
Advanced algorithms and proven methodologies
deliver accurate, evidence-based outcome
measures in Alzheimer’s and other CNS diseases.
Strong Partnerships & Global Impact:
Maturing Financials & Market Growth:
Trusted by 200+ global companies, we demonstrate
scalable impact and a proven record in advancing
cognitive health insights.
Consistent revenue growth, strong margins, robust
cash, and no debt. Well-positioned in digital health,
AI, and clinical research sectors.
3
Profitable Growth
Revenue & Profitability,
by Financial Year
60
US$ Million
50
Cogstate’s FY2025 is characterised by:
40
61%
30
58%
20
56%
51%
•
Robust growth in clinical trials customer and
vendor partner relationships.
•
Expansion into new opportunities in brain
health and neuroscience.
•
Operational leverage through digital
innovation.
•
Disciplined cost control.
54%
26%
24%
10
16%
18%
7%
0
FY21
Revenue
FY22
FY23
Gross Profit
FY24
FY25
Profit Before Tax
4
FY25 Operational and Financial Highlights
All figures in US$, unless stated
Revenue Growth
Total revenue of $53.1 million, up 22%. Clinical Trials revenue $50.6 million, up 28%.
Record Profit
Profit before tax $13.9 million, up 96%. NPAT $10.1 million, up 86%.
Margin Expansion
Gross margin of 61%, EBITDA margin of 30%, and EBIT margin of 25%.
Capital Efficiency
$11.5 million operating cash flow. Cash balance $35.6 million (after $4.8 million share buy-back).
Maiden Dividend
Declared
Fully franked annual dividend of A$0.02 per ordinary share declared post year-end.
Clinical Trials
Momentum
Clinical Trials sales contracts $41.3 million, up 53%. $14.1 million executed since 01-Jul-2025
Healthcare Opportunity
Rising demand for brain health insights continue to emerge -- Eisai license amendment enabling
broader use of technology as trial pre-screening tool.
5
FY25 Growth Drivers
•
1
2
3
Business as Usual
Sources of Trial Revenue
Margin Expansion
Growth in sales contracts
delivering strong in-period
revenue growth
•
Diversified book of business
enabled growth beyond phase 3
Alzheimer's trials into new
indications
•
License fees above 20% of
revenue
•
Orexin in sleep disorders
•
•
Continued increase in R&D spend
in rare diseases
Operating leverage associated
with revenue growth
•
Higher license fee revenue mix
•
Use of technology to create
efficiency and expand margins
•
Renewed interest in psychiatry
following drug approval and M&A
in Schizophrenia and promising
psychedelic programs in
Depression
•
Neurodegenerative disorders such
as Huntington’s and Parkinson’s
6
Capital Allocation
•
•
Maiden fully franked annual dividend of A$0.02
per share for FY25, reflecting confidence in
long-term growth and cash generation.
Over last 2.5 years, share buy-back has resulted
in cancellation of approx. 6% of issued shares.
•
•
FY25: 5.87m shares at avg. share price of A$1.30
Strong balance sheet supporting disciplined
investment and shareholder returns.
Dividend Timetable
28 Aug 2025
Record Date
29 Sept 2025
Payment Date
Capital Management Priorities
•
Strategic growth initiatives: Targeting
opportunities that align with strategy, enhance
capabilities, and build long-term value.
•
Investment in innovation: Funding product and
service development to drive growth and
competitiveness.
•
Capital returns: Flexible share buybacks when
valuation is compelling.
•
Sustainable dividends: Targeting annual dividend
payout ratio of 20% - 50% of NPAT, while
retaining sufficient capital for growth and
innovation.
7
Summary Statement of Group Profit or Loss
US$ millions
FY25
FY24
YTY %
Revenue
53.1
43.4
22%
Gross Profit
32.4
24.6
32%
GP%
61%
57%
4% Pts
Operating Expense
(16.5)
(15.3)
(8%)
EBITDA
16.0
9.3
72%
EBITDA Margin
30%
21%
9% pts
Depreciation & Amortization
(2.9)
(2.7)
(7%)
EBIT
13.0
6.5
100%
EBIT%
25%
15%
10% Pts
Net Interest
0.9
0.6
54%
Net Profit Before Tax
13.9
7.1
96%
Net Profit After Tax
10.1
5.4
86%
•
Revenue growth in Clinical Trials
partially offset by decline in Healthcare
(see next page for details).
•
Gross margin growth from higher
software license mix, ongoing resource
and cost management, and business
operational leverage.
•
EBITDA and EBIT margins at target
levels.
•
Record Net Profit before Tax.
8
Summary Statement of Segment Profit or Loss
Clinical Trials
Clinical Trials (including Research)
US$ millions
FY25
FY24
YTY %
Revenue
50.6
39.4
28%
Direct Costs (excluding depreciation)
(16.1)
(13.5)
(19%)
SG&A
(3.9)
(4.2)
7%
Gross Contribution
30.6
21.7
41%
60%
55%
5% Pts
GP%
Healthcare
Revenue
2.5
4.0
(37%)
Direct Costs
(0.6)
(1.1)
42%
Gross Contribution
1.9
2.9
(35%)
74%
72%
2% Pts
GP%
•
Revenue growth resulting from high in-year
revenue yield from improved new contract
sales.
•
Gross margin improvement from higher
software license mix, ongoing resource and
cost management, and operational leverage.
Healthcare
•
Revenue decline due to renegotiated global
licensing agreement in FY24.
•
Margin improvement reflects cost
management.
•
$1.2m trial pre-screening revenue included in
Clinical Trials segment
9
Summary Statement of Cash Flow
US$ millions
FY25
FY24
YTY %
Net Profit after Tax
10.1
5.4
86%
Interest Income
(0.9)
(0.6)
53%
Depreciation & Amortization
2.9
2.7
8%
Disposal of Assets
0.0
(0.1)
(100%)
Non-cash employee benefits
0.5
0.8
(32%)
Grant funding received
(0.3)
(0.3)
0%
Exchange Rate differences
(0.0)
(0.1)
(89%)
Change in working capital
(0.8)
(2.0)
(56%)
Operating Cash Flow
11.5
5.8
Cash Flow used in investing activities
(2.2)
Cash flow used in Financing activities
Total Cash Flow
•
Operating cash flow growth reflects the
strength in the Clinical Trials business,
ongoing cost management, and improved
working capital management.
•
Increased software capitalisation as a result
of increased investment in products, including
pending AI based products.
98%
•
Growth in financing cash flow includes $4.8m
of share buy back.
(1.1)
101%
•
Total cash has grown $5.4m year to year,
after accounting for the share buy-back.
(3.8)
(3.2)
18%
5.4
1.5
276%
10
Future Contracted Revenue Run-Off
Analysis
35.0
$35.9m FY26 revenue under contract at 21-Aug-2025
• $31.5m FY26 revenue under contract as at 30-Jun-2025
30.0
o Clinical Trials $29.2m, up 9% YTY (see table)
25.0
o Healthcare $2.3m, consistent with FY25.
20.0
• $4.4m from new contract sales of $14.1m executed since
01-Jul-2025
15.0
Clinical Trials Backlog Run-Off Comparison
30 June 2025
10.0
5.0
FY26
FY27
Clinical Trials
FY28
FY29+
FY30+
Healthcare
Clinical Trials revenue backlog $76.3m at 30-Jun-25 vs $85.6m at 30-Jun-24
30 June 2024
FY26
$29.2m
FY’25
$26.8m
FY27
$19.1m
FY’26
$21.0m
FY28
$10.8m
FY’27
$14.1m
FY29
$13.8m
FY’28
$10.3m
FY30+
$3.4m
FY’29+
$13.4m
Total
$76.3m
Total
$85.6m
11
Cogstate Medidata Partnership
Power Smarter Treatments and Healthier People
Leading provider of data capture, data analytics and clinical trial management systems
Expansion into CNS disease and Cogstate partnership announced October 2024
12
Building Momentum Together – Partnership Highlights
Shared Wins
Multiple joint awards in areas of
Long Covid, Parkinson’s Disease,
Rare and Alzheimer’s disease.
Large and growing pipeline, with
significant ramp up since
commercial team training Feb
2025.
Integrated Tech & Workflows
Joint Go to Market Highlights
•
Joint sales enablement program,
including eBooks, topic guides, fact
sheets, CNS blogs & presentations
•
Partnership recognised with 2025
MedTech Breakthrough Award
•
Joint events, including CNS webinar
series and conference schedule
•
LinkedIn program and CNS adwords campaign
Robust commercial process for
review of every CNS protocol
assessed for Cogstate fit.
13
Transformative Impact – Cogstate Solutions in Action
Measuring Brain Impacts of Paediatric Oncology
Treatments
FDA Approval for Alzheimer’s Disease Therapeutic
•
Oversaw all aspects of clinical outcome data quality for a successful global
Phase 3 Alzheimer’s drug trial that achieved FDA marketing approval.
•
Replaced long and burdensome neurocognitive tests with brief, digital,
game-like assessments for children ages 4–11 in a global leukaemia trial.
•
Rapidly scaled rigorous rater training, qualification and central review of
outcomes data through our leading platform and experts around the world.
•
Achieved >86% completion rates, overcoming previous data gaps and site
limitations.
•
Ensured accurate and high fidelity measures across hundreds of sites for
optimized signal to noise.
•
Enabled efficient, conclusive study results and improved participant
satisfaction.
Demonstrating Cognitive Safety of Antidepressant
Medications
•
•
•
Sponsor sought to evaluate the effects of esketamine on cognitive
functioning for global pivotal trials in treatment resistant depression
Given the mechanism (NMDA neurotransmission) it was critical the
cognitive assessment be robust, sensitive and acceptable to regulators.
The sponsor successfully characterized cognitive effects as part of first-inclass drug approval.
Endpoint Development and Full Regulatory Support
for a Rare Disease Program
•
Protocol and key endpoint development, including validation of the primary
endpoint by Cogstate.
•
Multiple FDA interactions (Pre-IND, End-of-Phase 2, COA, and Type C
meetings) to align on study endpoints and trial design.
•
Implementation of central rating for study endpoints to ensure consistency.
14
Outlook: Catalysts and Growth Levers for FY26 and Beyond
Medidata partnership
scaling
While FY25 saw pipeline build, FY26 is expected to deliver increased revenue from the Medidata
partnership, expanding reach across new CNS indications and customer segments.
AI product launch
Commercial launch of Cogstate’s first AI-powered product is anticipated in FY26, supporting further
automation, scalability, and differentiation.
Indication expansion
As we expand our offering in psychiatric and mood trials, we are seeing immediate traction.
Over $4m of sales contracts in these indications already executed in FY26 YTD.
Alzheimer’s data
catalyst
Potential for upcoming trial readout in Alzheimer’s could drive increased commercial opportunity,
both in clinical trials and community settings, and reinforce Cogstate’s leadership.
Ready to add scale
With a strong balance sheet, proven operating leverage, and expanding partnerships, Cogstate is
well-placed to capitalise on rising global investment in CNS R&D.
15
FY26 Outlook
Strong start to FY26
Since 01 July 2025, Cogstate has executed clinical trials sales contracts to the value of $14.1
million, compared to a full year FY25 result of $41.3 million.
Contracted revenue
$35.9 million of contracted FY26 revenue, including $31.5m contracted at 30-Jun-25 and a further
$4.4 million of revenue expected to be recognised from $14.1m of FY26 sales contracts executed.
Revenue Growth
Revenue growth expected to continue, but no specific guidance at this time, pending execution of
additional sales contracts to provide greater certainty in respect of timing of revenue.
Invest For Growth
Direct costs and operating costs will increase from FY25 to FY26 as Cogstate invests for growth:
• Additional science resources to support expansion into psychiatry and mood disorders;
• Additional resources based in the Asia-Pacific region to support growing customer base there;
• Continued increase in expenditure related to data engineering to bring more automated data
insights to Cogstate customers; and
• Engineering expenses associated with development of AI tools.
Subject to revenue growth in FY26, the increase in expenditure may result in a small decrease in
Potential Margin Impact margins (0-3 percentage points) from FY25 to FY26.
Capital Allocation
The Board will maintain flexibility to execute the share buyback, where there is a compelling case.
16
Cogstate Investor Insights Series – Upcoming Events
Annual General Meeting of Shareholders
Thursday 16 October 2025 at 11am AEST
Virtual and in person – Melbourne
Shareholder Day (in-person): Melbourne
Friday 7th November 2025 from 8:45am-2.30pm AEDT
Registrations Now Open via Cogstate Investor Hub
17
A Compelling Investment Proposition
Industry-Leading,
Tech-Driven
Platform:
Critical Partner in
CNS Clinical
Research:
Driving Innovation
in Clinical
Research:
Positioned at the
intersection of digital
health, neuroscience,
and AI-enablement;
within key growth
sectors with increasing
demand for scalable
solutions in clinical
research.
Proven track record,
expanding industry
partnerships, and a
technology platform
validated by decades
of research and
accepted by regulators;
primed for accelerated
growth.
As biopharma
accelerates adoption of
decentralised trials and
digital endpoints, our
expertise and
technology are
increasingly
indispensable.
Profitable Growth:
Financial
Momentum:
Transitioned to strong
profitability, generating
pre-tax profits and
achieving a 20% return
on capital deployed,
above the industry
average.
Record revenues,
consistently high gross
and EBIT margins and
robust operating cash
flow, with strong
balance sheet and no
debt.
Maiden fully franked
dividend declared.
18
Share your feedback
Discover